Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

NNASDAQ:TNGX
24.17
USD
-1.33
(-5.22%)
-1.39EPS
4.22BMarket Cap
Mar 29Next Earn
Tango Therapeutics, Inc.
NASDAQ:TNGX
(Nasdaq Stock Market)

Recent

price

24.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
USD
0.09
0.6
0.28
0.39
0.39
0.54
- -
Revenue per Share
-0.59
-0.94
-1.23
-1.08
-1.19
-0.87
-1.39
Basic EPS, GAAP
0.79
-0.99
-1.33
-1.26
-1.21
-1.2
-1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.44
3.94
2.83
2.48
1.85
2.55
5.79
Book Value per Share
0.44
3.94
2.83
2.48
1.85
2.55
5.79
Tangible Book Value per Share
87
62
88
95
109
116
150
Basic Weighted Avg Shares
8
37
25
37
42
62
- -
Sales/Revenue/Turnover
-681.82
-157.09
-446.79
-312.57
-346.09
-178.39
- -
Operating Margin (%)
1
1
2
2
2
2
2
Depreciation Expense
-52
-58
-108
-102
-130
-102
-208
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-678.84
-157.21
-435.14
-278.54
-309.73
-162.85
- -
Profit Margin (%)
153
452
320
301
228
332
968
Working Capital
7
- -
39
37
34
31
28
LT Debt
39
345
249
253
200
346
980
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-30.38
-36.41
-40.49
-57.58
-37.23
-36.48
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
30
29
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
144
168
169
Market Capitalization
3,016
5,264
4,222

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
392
1,032
993
Cash, Cash Equivalents & STI
380
1,014
978
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
20
25
Payables & Accruals
10
15
20
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
163.86%
73.51%
Free Cash Flow
- -
-15.97%
5.81%
Net Income, GAAP
- -
19.58%
-22.03%
Sales/Revenue/Turnover
- -
92.27%
48.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
20
12
4
42
2025
5
3
54
- -
62
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.35
-0.24
-0.27
-0.35
-1.19
2025
-0.36
-0.35
0.14
-0.29
-0.87
2026
-0.32
-0.37
-0.39
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company that discovers and develops precision medicines targeting cancer vulnerabilities, with a focus on mutant-selective and tumor-specific programs. The company offers a pipeline of novel small-molecule therapeutics, including TNG456 (first-in-class PRMT5-methyltransferase inhibitor for MTAP-deleted tumors), TNG348 (first-in-class MTA-cooperative PRMT5 inhibitor for solid tumors), TNG908 (brain penetrant LSD1 inhibitor for small cell lung cancer), and earlier-stage programs such as TNG462 (PRMT5 inhibitor for splicing factor mutant cancers) and discovery-stage assets targeting p53 and MRE11; these programs leverage the company's proprietary precision oncology platform combining bioinformatics, functional genomics, and chemistry to identify tumor cell dependencies. Tango Therapeutics operates primarily in the United States, with headquarters in Boston, Massachusetts, founded in 2019. Recent developments include the dosing of the first patient in the Phase 1/2 clinical trial of TNG348 in October 2024, positive initial data from the Phase 1/2 trial of TNG456 presented at ESMO 2024 showing clinical activity in MTAP-deleted pancreatic, NSCLC, and mesothelioma cancers, and the company's collaboration with Verastem Oncology to evaluate TNG456 in combination with avutometinib and defactinib in KRAS G12C mutant cancers announced in 2024.

Company News

  • Tango Therapeutics, Inc. $TNGX Stock Acquired by Fisher Asset Management LLC

  • Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss

  • Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

  • Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

  • Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference

  • Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity

  • Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

  • TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

  • Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

  • Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

  • Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

  • Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

  • Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

  • Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

  • Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey

  • Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

  • Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

  • Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference